[
Abstract]
[
Full Text PDF] （in Japanese / 1820KB）
[Members Only And Two Factor Auth.][
Back to Search Results]
J.Jpn. Surg. Soc.. 92(9): 1330-1333, 1991
Report on the annual meeting
ADOPTED IMMUNOCHEMOTHERAPY USING IL-2 AND SPLEEN LAK CELL
―RANDOMIZED STUDY―
Thirty patients with hepatoceullar carcinoma who underwent hepatic resection during the recent 2 years in our department were randomized. We derived LAK cells from the autologous spleen removed during operation. The cultivation of LAK cells were done with IL-2. Adriamycin 20mg/body was injected into hepatic artery via subcutaneous implanted reservoir on the 8th postoperative day. In group A, 1.0～7.6×10
9 LAK cells were injected i. a on day, 10, 14, and 21 after operation. IL-2 of 5×10
5 JU were also injected i.a. during 3 weeks. Group B patients were treated only by adriamycin. High fever was seen in all patients belonged to group A. Twelve patients in each group were evaluable. Recurrence rate 8.3% in group A was significantly lower than 50% in group B. In experimental study, accumulation of
111In-oxine labelled LAK cells in mouse 3LL lung cancer was augumented in splenectomized ones. Adopted immunotherapy by spleen LAK-cells may be effective and safe treatment to preventing recurrence of hepatocellular carcinoma after hepatectomy.
Go to Page Top
To read the PDF file you will need Adobe Reader installed on your computer.